Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Эналаприл: новые возможности

Полный текст:

Аннотация

В обзоре представлены данные современных исследований эналаприла, открывающие новые свойства этого препарата, расширяющие представление о его лечебном эффекте.

Об авторе

Е. О. Таратухин
Российский научно-исследовательский медицинский университет им. Н.И. Пирогова, Москва
Россия
ассистент кафедры госпитальной терапии №1 лечебного факультета


Список литературы

1. Katzung BG. Basic and clinical pharmacology. 10th ed. McGrawHill 2007; 1179c.

2. Ma J, Lee K-V, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension. Hypertension 2006; 48: 846-52.

3. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circulation J 2012; 76: 268-77.

4. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with ACE inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348(7): 583-92.

5. Nissen SE, Tuzcu EM, Libbi P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: a randomized controlled trial. JAMA 2004; 292: 2217-25.

6. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of longstanding persistent atrial fibrillation: results of prospective and controlled study. Eur Heart J 2003; 24: 2090-8.

7. Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185-91.

8. Bosch X, Esteve J, Sitges M, et al. Prevention of chemotherapy-induced LV dysfunction woth enalapril and carvedilol: rationale and design of the OVERCOME trial. J Card Fail 2011; 17: 643-8.

9. Krysiak R, Okopieá B. Lymphocyte-suppressing action of angiotensin-converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151-61.

10. Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765-72.

11. Cacciatore F, Bruzzese G, Vitale DF, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage and oxidative stress in hypertensive patients. Eur J Clin Pharmacol 2011; 67: 877-93.

12. Georgakopoulous P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients. Am J Hematol 2010; 85: 894-6.

13. Zou D, Grote L, Eder DN, et al. A double-blind, crossover study of doxazosin and enalapril on peripheral vascular tone and nocturnal BP in sleep apnea patients. Sleep Med 2010; 11: 325-8.

14. Hoque R, Rahman MS, Iqbal M, et al. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Bangl Med Res Counc Bull 2009; 35: 44-8.

15. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in pype 1 diabetes. N Engl J Med 2009; 361: 40-51.

16. Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885-93.

17. Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers longterm protection against target organ damage. Hypertens Res 2012; 35: 604-10.

18. Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16. (в печати).

19. Silva PS, Fontana V, Luizon MR, et al. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 2012; Jun, 17. (в печати).

20. Perkins BA, Sochett EB, Cherney DZ. Ability of cystatin C to detect changes in glomerular filtration rate after ACE inhibition in patients with uncomplicated type 1 diabetes. Clin Exp Hypertens 2012; Jun,11. (в печати).

21. Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110-20.

22. Taddei S. Fixed-dose combination therapy in hypertension. High Blood Pres 2012; 19(2): 55-7.

23. Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis 2012; 2(3): 160-70.

24. Chobanian AV, Bakris GL, Black HR, et al. National HLB Institute JNC on prevention, detection, evaluation and treatment of High Blood Pressure. The Seventh report of the National Comittee. JAMA 2003; 289: 2560-72.

25. Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-Analysis of DoseResponse Relationships for Hydrochlorothiazide, Chlorthalidone and Bendroflumethiazide on blood Pressure, serum Potassium and Urate. Hypertension 2012; 59: 1104-9.


Для цитирования:


Таратухин Е.О. Эналаприл: новые возможности. Кардиоваскулярная терапия и профилактика. 2012;11(5):71-73.

For citation:


Taratukhin E.O. Enalapril: new possibilities. Cardiovascular Therapy and Prevention. 2012;11(5):71-73. (In Russ.)

Просмотров: 22


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)